<DOC>
	<DOCNO>NCT01030822</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity , safety reactogenicity booster dose pneumococcal vaccine GSK1024850A administer either 9-18 month 15-18 month age child prim primary study NCT00814710 . This study also aim assess persistence antibody induce follow primary vaccination pneumococcal vaccine GSK1024850A primary study NCT00814710 prior booster vaccination follow vaccination present study approximately 24 month age . The study also design evaluate immunogenicity , safety reactogenicity pneumococcal vaccine GSK1024850A administer catch-up vaccination ( 2+1 ) second year life child unprimed vaccine GSK1024850A study NCT00814710 .</brief_summary>
	<brief_title>Booster Catch-up Vaccination With Vaccine GSK1024850A</brief_title>
	<detailed_description>The study randomize primed subject non-randomized unprimed subject . The protocol posting update accord amendment protocol date 16 April 2010 . The age range time randomization subject prim study NCT00814710 age range booster vaccination one group extend .</detailed_description>
	<mesh_term>Streptococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject investigator believe parent ( ) / guardian ( ) comply requirement protocol . Written , sign thumbprinted informed consent obtain parent ( ) /guardian ( ) child/ward . Where parent ( ) /guardian ( ) illiterate , consent form countersign witness . Healthy subject establish medical history clinical examination enter study . For primed subject : Completion full vaccination course study NCT00814710 . 918 month age time randomization . Group A : 918 month age time booster vaccination . Group B : 1518 month age time booster vaccination . For unprimed subject ( Group C ) : Enrolled study NCT00814710 . 1218 month age time first vaccination . Use investigational nonregistered product within 30 day precede vaccination , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product . Chronic administration immunosuppressant immunemodifying drug within six month prior vaccination . Administration immunoglobulins and/or blood product within three month precede vaccination plan administration study period . Administration pneumococcal vaccine since end study NCT00814710 . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History reaction allergic disease likely exacerbate component vaccine . Major congenital defect serious chronic illness . History neurologic disorder seizure . Acute disease time enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>9 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Catch-up vaccination</keyword>
	<keyword>Safety</keyword>
	<keyword>Pneumococcal vaccine</keyword>
	<keyword>Pneumococcal disease</keyword>
	<keyword>Booster vaccination</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>